4.6 Article

Photovoltaic Restoration of Central Vision in Atrophic Age-Related Macular Degeneration

Journal

OPHTHALMOLOGY
Volume 127, Issue 8, Pages 1097-1104

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2020.02.024

Keywords

-

Categories

Funding

  1. Pixium Vision, Paris, France
  2. Sight Again Project (via Structural R&D Projects for Competitiveness and Investment for the Future)
  3. National Institutes of Health, Bethesda, Maryland [R01-EY027786]
  4. Biomedical Research Centre at Moorfields Eye Hospital - National Institute for Health Research, United Kingdom
  5. Clinical Investigation Center at the Quinze-Vingts National Hospital - Inserm-DHOS, France

Ask authors/readers for more resources

Purpose: Loss of photoreceptors in atrophic age-related macular degeneration results in severe visual impairment, although some peripheral vision is retained. To restore central vision without compromising the residual peripheral field, we developed a wireless photovoltaic retinal implant (PRIMA; Pixium Vision, Paris, France) in which pixels convert images projected from video glasses using near-infrared light into electric current to stimulate the nearby inner retinal neurons. Design: We carried out a first-in-human clinical trial to test the safety and efficacy of the prosthesis in patients with geographic atrophy (ClinicalTrials.gov identifier, NCT03333954). Participants: Five patients with geographic atrophy zone of at least 3 optic disc diameters, no foveal light perception, and best-corrected visual acuity of 20/400 to 20/1000 in the worse-seeing study eye. Methods: The 2-mm wide, 30-mm thick chip, containing 378 pixels (each 100 mm in diameter), was implanted subretinally in the area of atrophy (absolute scotoma). Main Outcome Measures: Anatomic outcomes were assessed with fundus photography and OCT for up to 12 months of follow-up. Prosthetic vision was assessed by mapping light perception, bar orientation, letter recognition, and Landolt C acuity. Results: In all patients, the prosthesis was implanted successfully under the macula, although in 2 patients, it was implanted in unintended locations: within the choroid and off center by 2 mm. All 5 patients could perceive white-yellow prosthetic visual patterns with adjustable brightness in the previous scotomata. The 3 with optimal placement of the implant demonstrated prosthetic acuity of 20/460 to 20/550, and the patient with the off-center implant demonstrated 20/800 acuity. Residual natural acuity did not decrease after implantation in any patient. Conclusions: Implantation of the PRIMA did not decrease the residual natural acuity, and it restored visual sensitivity in the former scotoma in each of the 5 patients. In 3 patients with the proper placement of the chip, prosthetic visual acuity was only 10% to 30% less than the level expected from the pixel pitch (20/420). Therefore, the use of optical or electronic magnification in the glasses as well as smaller pixels in future implants may improve visual acuity even further. (C) 2020 by the American Academy of Ophthalmology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available